SSTR PET → PRRT
SSTR PET followed by PRRT is the original theranostic pair: the scan with the diagnostic isotope decides who gets the same molecule with the therapeutic isotope.
NETTER-1/2 and COMPETE required SSTR-avid disease on imaging; uptake intensity (Krenning ≥3) and absence of FDG-avid SSTR-negative lesions predict benefit. The template later copied by PSMA theranostics.
Pages like this
not linked directly; found by shared links- TrialCOMPETE
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- IdeaDosimetry-personalised PRRT instead of four fixed cycles
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours.
- ProductGallium-68 DOTATATE (and Cu-64 DOTATATE)
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Peptide receptor radionuclide therapy (PRRT), Theranostics, Somatostatin receptor 2.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Peptide receptor radionuclide therapy (PRRT), Theranostics, Somatostatin receptor 2, Neuroendocrine tumours.
- PersonEmily K. Bergsland
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours.
- InstitutionHolden Comprehensive Cancer Center, University of Iowa
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours.